ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Zocilurtatug Pelitecan

Also written as “ZL-1310” and “ZL-1310 in combination with Atezolizumab or Durvalumab”.

Its studies are mostly in Small Cell Lung Carcinoma, led by 3 companies.

Drug pageZocilurtatug Pelitecan: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 8, 20256 company-led studies, 6 open or runningNext primary completion: May 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zai Labits history only44 open or runningphase 3since Oct 8, 2025Dec 7, 2023May 30, 2027phase 1 · NCT06179069
Amgen11 open or runningphase 1since Apr 9, 2026Apr 9, 2026May 21, 2028phase 1 · NCT07531095
Boehringer Ingelheimits history only11 open or runningphase 2since Jul 13, 2026Jul 13, 2026Apr 26, 2030phase 2 · NCT07707895

Also a collaborator on its studies: Zai Lab (US).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Amgen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 29, 2026Named zocilurtatug pelitecanINNProposed as its International Nonproprietary Name in WHO's List 134 · before, ZL-1310
  2. Apr 9, 2026First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT07531095 · 160 planned · United States, Australia, Belgium and more

Ahead

  1. May 21, 2028Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT07531095

TargetBeta

DLL3 →read by rule
“An antibody-drug conjugate (ADC) composed of zocilurtatug, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) and ”NCIt, by rule

Other programs on DLL3

ProgramCompanyFurthest phaseStudies
tarlatamabruleAmgenphase 313
AlveltamigruleSuzhou Zelgen Biopharmaceuticalsphase 311
obrixtamigBoehringer Ingelheimphase 311
Anti-DLL3 Antibody-drug Conjugate BL-M14D1Sichuan Biokin Pharmaceuticalphase 34
gocatamigMerckphase 34
Autologous Anti-DLL3 CAR-T Cells DJI136Novartisphase 22
Anti-DLL3 Antibody-drug Conjugate IDE849ideaya-biosciencesphase 22
SHR-7787Jiangsu HengRui Medicinephase 21
Anti-DLL3 Antibody-drug Conjugate FZ-AD005ruleShanghai Fudan-Zhangjiang Bio-Pharmaceuticalphase 12
clesitamigHoffmann-La Rochephase 12
Actinium Ac 225-ABD147ruleabdera-therapeutics-incphase 11
Indium In 111-ETN029Novartisphase 11

Studies

The one study Amgen leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07531095Small Cell Lung Carcinoma · United States, Australia, Belgium and more1RecruitingMay 21, 2028160

How it is read

Names in the registry

  • “ZL-1310”, 5 entries
  • “ZL-1310 in combination with Atezolizumab or Durvalumab”, 1 entry

Codes read as this program: ZL1310.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.